Core Insights - Elutia Inc. has launched EluPro™, the first FDA-cleared antibiotic-eluting biomatrix for use with cardiac implantable electronic devices (CIEDs) and neurostimulators, marking a significant innovation in the medical device industry [1][2][3] Company Overview - Elutia focuses on developing drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients, with a mission to humanize medicine [5] Product Launch Details - The launch of EluPro follows a successful pilot program that demonstrated strong physician adoption and positive patient outcomes, with orders increasing over 50% post-approval by hospital value analysis committees [2][3] - EluPro combines antibiotics rifampin and minocycline with a regenerative biomatrix, addressing infection prevention and promoting healing, which is critical given the 5-7% complication rates associated with CIEDs [3] Market Context - Over 600,000 CIEDs are implanted annually in the U.S., with a market value of $600 million for CIED protection, highlighting the potential for EluPro to capture significant market share [3]
Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand